New perspectives on Nordic research: Nordic EMBL Partnership Meeting 2018

NCMM hosted the 9th annual Nordic EMBL Partnership Meeting in the hills above Oslo. The annual Partnership meetings offer researchers an opportunity to come together for a programme of scientific discussion and networking.

This year’s Nordic EMBL Partnership meeting, the 9^th annual meeting in the Partnership’s history, saw over 150 participants gather in Oslo.

Visitors from DANDRITE (Danish Institute for Translational Neuroscience), MIMS (Molecular Infection Medicine Sweden), FIMM (Institute for Molecular Medicine Finland) and the EMBL joined NCMM’s group leaders and researchers at the Soria Moria Hotel. The setting in the hills above Oslo offered participants some fantastic views of the city and the Oslofjord, making for a stimulating meeting location.

Read the article on the website of The Nordic EMBL Partnership for Molecular Medicine

Fernström Prize for research on bacterial cell walls

2018 Fernström Prize awardee at Umeå University becomes Felipe Cava. His research group studies how bacteria can adapt the construction of the cell wall to different host environments, knowledge that may be important for the development of new antibiotics.

Felipe Cava will be honored for the Fernstrom Prize at Umeå University's annual festival on Saturday, October 20th. The actual award ceremony takes place during Research Day at Lund University in November.

Read more: Fernström Prize for research on bacterial cell walls

A new toxin in Cholera bacteria discovered by scientists in Umeå

[2018-06-21] Scientists affiliated with MIMS and UCMR describe their findings about a new toxin and its secretion mechanism from the major bacterial pathogen Vibrio cholerae in a recent publication in the journal Communications Biology (7 June 2018).

The bacterium Vibrio cholerae was discovered more than 150 years ago but remains as one of the main causes of bacterial infectious disease globally, especially in low-income nations where it occurs endemic, and outbreaks of cholera disease can lead to major epidemics.

In addition to causing cholera disease characterized by very severe watery diarrhea, different variants of V. cholerae can cause, for example, wound infections and infections in the ear canal (ear inflammation). If the infection is reaching the bloodstream, it can lead to blood poisoning. Such variants of Vibrio bacteria are common in brackish water, but can be found both in freshwater and saltwater and are also present in such environments in our country.

Scientists from Umeå University have now discovered and characterised the structure and function of a so far unknown Vibrio toxin. A team led by Professor Sun Nyunt Wai at Department of Molecular Biology and MIMS used the worm Caenorhabditis elegans as a predatory host for the bacteria and identified by molecular genetic analysis the V. cholerae genes required for production and release of the new protein toxin, now called MakA.

Read more: A new toxin in Cholera bacteria discovered by scientists in Umeå

Treatment of cancer could become possible with adenovirus

[2018-04-19] An international team of researchers led by professor Niklas Arnberg at Umeå University, shows that adenovirus binds to a specific type of carbohydrate that is overexpressed on certain types of cancer cells. The discovery opens up new opportunities for the development of virus-based cancer therapy. The study is published in the latest issue of the scientific journal "Proceedings of the National Academy of Sciences of USA",  PNAS April 19, 2018.

Adenovirus is a common virus that causes infectious diseases of the respiratory tract, eyes and gastrointestinal tract in humans and animals. Researchers at Umeå University study molecular mechanisms of infection in order to understand how adenovirus causes disease.
The researchers in Umeå, together with research groups from Germany, the UK and Hungary, have now discovered a new type of mechanism used by a rare adenovirus type to attack cells.

Read more: Treatment of cancer could become possible with adenovirus

Oliver Billker appointed new Director of MIMS

[2018-04-17] MIMS proudly announces that Dr. Oliver Billker from the Wellcome Sanger Institute, Cambridge, UK, has been recruited as future director of MIMS. Dr. Oliver Billker is a distinguished expert in malaria parasite genomics. In October 2018, he will succeed the founding Director of MIMS, Professor Bernt Eric Uhlin, who has held the role since 2007.

The search committee, which was led by the chair of the MIMS Executive Board, Professor Carl-Henrik Heldin, also included Professor Iain Mattaj, Director General for EMBL (European Molecular Biology Laboratory).
“I am very pleased that Dr. Oliver Billker has accepted to be the next director of MIMS,” says Professor Carl-Henrik Heldin.
“With his outstanding scientific credentials, extensive international network and excellent leadership skills, he is the perfect person to lead this very successful institute.”

“Oliver Billker is an excellent choice to lead MIMS”, adds Professor Iain Mattaj.
“His experience in the large-scale genetics and genomics of malaria parasites and his participation in international collaborations will be valuable additions to the MIMS portfolio”.

Read more: Oliver Billker appointed new Director of MIMS